IMRN Projected Dividend Yield
ADR (Sponsored)/Immuron Ltd ( NASDAQ : IMRN )Immuron is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a class of polyclonal antibodies. Co.'s oral polyclonal antibodies provide delivery within the gastrointestinal track but do not cross into the bloodstream. Co. markets its commercial products Travelan® and Protectyn® in Australia, both products are listed medicines on the Australian Register for Therapeutic Goods. Co. also markets Travelan® in Canada where it is licensed as a natural health product indicated to reduce the risk of travelers' diarrhea, and market Travelan® as a dietary supplement for digestive tract protection. 20 YEAR PERFORMANCE RESULTS |
IMRN Dividend History Detail IMRN Dividend News IMRN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |